-
Resolutions of Nightingale Health Plc’s Extraordinary General Meeting – Jun 29, 2022
-
Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2022 – 2023 – Jun 15, 2022
-
Notice to the Extraordinary General Meeting of Nightingale Health Plc – Jun 08, 2022
-
Conversion of Nightingale Health Plc’s Series A shares and EMP shares to Series B shares – May 19, 2022
-
Nightingale’s Board of Directors resolved on new share-based incentive plans – Mar 18, 2022
-
Nightingale Health Group’s Half-year report 1 July 2021 – 31 December 2021: Progressing faster than expected in line with strategy – Feb 24, 2022
-
Conversion of Nightingale Health Plc’s Series A shares to Series B shares – Feb 08, 2022
-
Nightingale has completed the acquisition of Finnish genetic testing company Negen – Feb 03, 2022
-
Nightingale introduces combination of its proprietary blood test and genomics: acquires Finnish genetic testing company Negen and launches international centre of excellence for genomic data analysis – Jan 18, 2022
-
Tuukka Paavola appointed as Chief Financial Officer of Nightingale Health Plc – Nov 02, 2021
-
Conversion of Nightingale Health Plc’s Series A shares and EMP shares to Series B shares – Oct 29, 2021
-
Resolutions of Nightingale Health Plc’s Annual General Meeting and Board of Directors – Oct 28, 2021
-
Nightingale and major Finnish pharmacy chain Yliopiston Apteekki enter into nation-wide distribution partnership of Nightingale’s at-home testing solution – Oct 27, 2021
-
Nightingale and Terveystalo launch a new well-being membership – Oct 13, 2021
-
Notice to the Annual General Meeting of Nightingale Health Plc – Oct 01, 2021
-
Nightingale’s Annual Report for financial year 2020–2021 published – Oct 01, 2021
-
Nightingale Health Plc Financial Statements Release 1 July 2020 – 30 June 2021 – Sep 15, 2021
-
Jeffrey Barrett appointed as Chief Scientific Officer of Nightingale Health Plc – Aug 30, 2021
-
Nightingale Health acquires German digital health company Yolife GmbH – Jul 09, 2021
-
Nightingale Health quarterly summary of achieved key milestones and reiteration of near-term business targets – Jul 01, 2021
-
Nightingale secures global scalability of its at-home solution by partnering with at-home blood collection device manufacturer Weavr with new commercial terms and minority investment – Jun 29, 2021
-
Nightingale successfully completes the first phase of its at-home blood testing pilot – Jun 23, 2021
-
Nightingale restructures its Management Team and establishes strategic partnership with Reaktor – May 04, 2021
-
Nightingale Health signed service agreement for health and well-being services in Japan – Apr 29, 2021
-
Nightingale Health Plc and Terveystalo have entered into strategic partnership agreement – Apr 22, 2021
-
Nightingale Health Plc’s subsidiary received clinical laboratory certification in Japan – Apr 09, 2021
-
The cancellation of Nightingale Health Plc’s treasury shares entered in the Trade Register – Mar 31, 2021
-
Nightingale Health Plc’s ten largest shareholders after the completion of the initial public offering – Mar 25, 2021
-
Stabilisation measures taken and the end of the stabilisation period; the Board of Directors has resolved on the cancellation of treasury shares – Mar 23, 2021
-
The IPO of Nightingale has been oversubscribed and the listing will be completed as planned – trading in the series B shares is expected to commence on 19 March 2021 – Mar 18, 2021
-
Public offering of Nightingale has been oversubscribed and therefore the subscription period has been discontinued – Mar 16, 2021
-
Nightingale Health Plc comments on the media coverage on its initial public offering – Mar 15, 2021
-
Nightingale announces a fixed subscription price and publishes a prospectus for its contemplated IPO and listing of its series B shares on Nasdaq First North Growth Market Finland – Mar 08, 2021
-
Nightingale has applied for its series B shares to be listed on Nasdaq First North Growth Market Finland and commences the initial public offering – Mar 08, 2021